BrainsWay Ltd. (BWAY)

BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.

BrainsWay's $5 million investment in Neurolief expands its mental health footprint with at-home depression treatment potential.

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Brainsway Ltd. Sponsored ADR (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The mean of analysts' price targets for Brainsway (BWAY) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call ...

Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.

Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.